Overexpression of ribosomal L1 domain containing 1 is associated with an aggressive phenotype and a poor prognosis in patients with prostate cancer

Li,Xiao‑Ping; Jiao,Ju; Lu,Li; Zou,Qiong; Zhu,Shu; Zhang,Yong

doi:10.3892/ol.2016.4294

April-2016 Volume 11 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

April-2016 Volume 11 Issue 4

Full Size Image

Article

Overexpression of ribosomal L1 domain containing 1 is associated with an aggressive phenotype and a poor prognosis in patients with prostate cancer

Authors:
- Xiao‑Ping Li
- Ju Jiao
- Li Lu
- Qiong Zou
- Shu Zhu
- Yong Zhang
View Affiliations / Copyright

Affiliations: Department of Nuclear Medicine, Third Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Urology, Sixth Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510655, P.R. China
Pages: 2839-2844
|
Published online on: March 1, 2016

https://doi.org/10.3892/ol.2016.4294
Expand metrics +

Abstract

The aim of the present study was to investigate the overexpression and significance of ribosomal L1 domain containing 1 (RSL1D1) in prostate cancer (PCA). The present study performed immunohistochemical analysis on the tissues of 138 patients with pathologically confirmed PCA. The patients were followed up for a median of 87 months. In addition, 50 patients with benign prostatic hyperplasia (BPH) were enrolled in the present study as a control group. Of the 138 PCA tissue samples, 124 (89.9%) expressed RSL1D1, while 4 out of the 50 (8.0%) BPH tissues expressed RSL1D1. The present study defined a high RSL1D1 expression level as the relative gene expression that was equal to or higher than the median, and low expression as the gene expression lower than the median. The pathological stage of patients with PCA (≥pT3a vs. pT2c) and the Gleason scores of patients (≥7 vs. <7) were associated with RSL1D1 expression (χ2=4.809 and 14.703; P=0.028 and P<0.0001, respectively) and a high expression of RSL1D1 (χ2=10.294 and 17.520; P=0.001 and P<0.0001, respectively). Kaplan‑Meier curve analysis demonstrated that the biochemical recurrence (BCR)‑free survival rate of the patients was increased in patients without RSL1D1 expression (P=0.0046), in those with low RSL1D1 expression (P<0.0001) and in those without RSL1D1 expression in the mesenchyme (P=0.006) compared with those patients with no expression, low expression and no mesenchymal expression, respectively. A high expression level of RSL1D1 was demonstrated to be an independent prognostic factor of BCR in patients with PCA using Cox regression analysis. Overall, the present study demonstrated that RSL1D1 expression was associated with PCA, and that it may aid in the improvement of diagnosis, prognosis and risk stratification of patients with PCA.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Gleason DF: Histologic grading of prostate cancer: A perspective. Hum Pathol. 23:273–279. 1992. View Article : Google Scholar : PubMed/NCBI
3	Ma L, Chang N, Guo S, Li Q, Zhang Z, Wang W and Tong T: CSIG inhibits PTEN translation in replicative senescence. Mol Cell Biol. 28:6290–6301. 2008. View Article : Google Scholar : PubMed/NCBI
4	Li N, Zhao G, Chen T, Xue L, Ma L, Niu J and Tong T: Nucleolar protein CSIG is required for p33ING1 function in UV-induced apoptosis. Cell Death Dis. 3:e2832012. View Article : Google Scholar : PubMed/NCBI
5	Shen MM and Abate-Shen C: Molecular genetics of prostate cancer: New prospects for old challenges. Genes Dev. 24:1967–2000. 2010. View Article : Google Scholar : PubMed/NCBI
6	Narita M and Lowe SW: Senescence comes of age. Nat Med. 11:920–922. 2005. View Article : Google Scholar : PubMed/NCBI
7	Campisi J: Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell. 120:513–522. 2005. View Article : Google Scholar : PubMed/NCBI
8	Campisi J: Aging, tumor suppression and cancer: High wire-act! Mech Ageing Dev. 126:51–58. 2005. View Article : Google Scholar : PubMed/NCBI
9	Collado M, Blasco MA and Serrano M: Cellular senescence in cancer and aging. Cell. 130:223–233. 2007. View Article : Google Scholar : PubMed/NCBI
10	Choi J, Shendrik I, Peacocke M, Peehl D, Buttyan R, Ikeguchi EF, Katz AE and Benson MC: Expression of senescence-associated beta-galactosidase in enlarged prostates from men with benign prostatic hyperplasia. Urology. 56:160–166. 2000. View Article : Google Scholar : PubMed/NCBI
11	Castro P, Giri D, Lamb D and Ittmann M: Cellular senescence in the pathogenesis of benign prostatic hyperplasia. Prostate. 55:30–38. 2003. View Article : Google Scholar : PubMed/NCBI
12	Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, et al: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725–730. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sobin LH, Gospodarowicz MK and Wittekind C: TNM Classification of Malignant Tumors (UICC). 1:(7th). Wiley-Blackwell. Hoboken, NY: 2009.
14	Epstein JI: An update of the Gleason grading system. J Urol. 183:433–440. 2010. View Article : Google Scholar : PubMed/NCBI
15	Prensner JR, Rubin MA, Wei JT and Chinnaiyan AM: Beyond PSA: The next generation of prostate cancer biomarkers. Sci Transl Med. 4:127rv32012. View Article : Google Scholar : PubMed/NCBI
16	Lilja H, Ulmert D and Vickers AJ: Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer. 8:268–278. 2008. View Article : Google Scholar : PubMed/NCBI
17	Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, et al: American Cancer Society Prostate Cancer Advisory Committee: American cancer society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin. 60:70–98. 2010. View Article : Google Scholar : PubMed/NCBI
18	Balk SP, Ko YJ and Bubley GJ: Biology of prostate-specific antigen. J Clin Oncol. 21:383–391. 2003. View Article : Google Scholar : PubMed/NCBI
19	Gleason DF and Mellinger GT: Veterans Administration Cooperative Urological Research Group: 1974. J Urol. 167:953–958. 2002. View Article : Google Scholar : PubMed/NCBI
20	Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC and Eisenberger MA: The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up. BJU Int. 109:32–39. 2012. View Article : Google Scholar : PubMed/NCBI
21	Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, et al: Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration. Eur Urol. 60:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
22	Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI and Walsh PC: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 169:517–523. 2003. View Article : Google Scholar : PubMed/NCBI
23	Miyake M, Tanaka N, Asakawa I, Morizawa Y, Anai S, Torimoto K, Aoki K, Yoneda T, Hasegawa M, Konishi N and Fujimoto K: Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: A retrospective study. Radiat Oncol. 9:2082014. View Article : Google Scholar : PubMed/NCBI
24	Cao D, Kibel AS, Gao F, Tao Y and Humphrey PA: The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence. Am J Surg Pathol. 34:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
25	Meng L, Yasumoto H and Tsai RY: Multiple controls regulate nucleostemin partitioning between nucleolus and nucleoplasm. J Cell Sci. 119:5124–5136. 2006. View Article : Google Scholar : PubMed/NCBI